Fiserv missed on the bottom line in a major way in the third quarter, and its stock plunged. It recently got a new CEO who's developing a plan to embed more AI in the business and meet consumer needs.

Vertex Pharmaceuticals' market-beating returns over the past 10 years wouldn't have been enough to turn $100,000 into $1 million. Though it still has strong prospects, this goal seems far too ...

The iPhone recently took the crown to become the world's top-selling smartphone. That's just the tip of the iceberg.